查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596760

胃癌治療市場：治療方法、適應症、藥物類別、給藥途徑、分銷管道分類 - 全球預測 2025-2030

Stomach Cancer Treatment Market by Treatment, Disease Indication, Drug Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年胃癌治療市場價值為50.9億美元，預計到2024年將達到55.5億美元，複合年成長率為9.53%，到2030年將達到96.3億美元。

胃癌治療的範圍和定義包括旨在控制和治癒胃癌的各種治療方法，包括手術、化療、標靶治療和免疫治療。胃癌是全球癌症相關死亡的首要原因之一，證明了治療的必要性，因此需要有效的治療策略來改善患者的預後和存活率。胃癌治療對於個人化醫療的應用至關重要，個人化醫療根據個體的遺傳傾向和癌症的分子特徵量身定做治療方法，從而促進更精確和有效的治療方法。最終用途範圍主要包括醫院、癌症研究中心和專門的癌症診所，多學科團隊正在這些地方部署這些治療方法來治療胃癌。

主要市場統計
基準年[2023] 50.9億美元
預測年份 [2024] 55.5億美元
預測年份 [2030] 96.3億美元
複合年成長率（%） 9.53%

有幾個關鍵的成長要素推動了市場格局，特別是標標靶治療的進步和盛行率的增加，推動了對創新治療方案的需求。健康意識的提高和診斷技術的改進也有助於市場成長，因為它們有利於早期發現和及時干預。此外，下一代免疫療法和聯合治療方案的開發也出現了新的潛在機會，並有望提高療效和患者的生活品質。鼓勵公司投資合作研究和臨床試驗來釋放這些機會。

然而，市場開拓面臨限制和挑戰，例如治療成本高、患者對治療的反應不同以及發展中地區獲得先進治療方案的機會有限。監管障礙和進行全球認可的臨床試驗的複雜性使市場擴張更加複雜。為了發展我們的業務，我們將透過專注於早期檢測和治療反應監測的生物標記、增強藥物輸送系統以及利用人工智慧來最佳化治療途徑來推動創新。市場競爭激烈且研究密集型，需要持續創新和策略聯盟才能保持競爭力並有效解決未滿足的需求。

市場動態：快速發展的胃癌治療市場的關鍵市場洞察

供給和需求的動態交互作用正在改變胃癌治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 胃癌高風險的老年人口增加
    • 久坐和不健康的生活方式導致糖尿病和肥胖症增加
    • 越來越重視早期篩檢和早期發現
  • 市場限制因素
    • 胃腸病專家短缺，及時診斷所需的檢測和治療方法有限
  • 市場機會
    • 胃癌治療和診斷方法的持續技術進步
  • 市場挑戰
    • 治療相關的副作用

波特五力：駕馭胃癌治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對胃癌治療市場的影響

外部宏觀環境因素在塑造胃癌治療市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解胃癌治療市場的競爭狀況

對胃癌治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣胃癌治療市場供應商績效評估

FPNV定位矩陣是評估胃癌治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製胃癌治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對胃癌治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 胃癌高風險的老年人口增加
      • 由於缺乏運動和不健康的生活習慣，糖尿病和肥胖患者不斷增加。
      • 早期篩檢和檢測的重要性日益增加
    • 抑制因素
      • 胃腸病專家短缺，及時診斷所需的掃描和治療手段有限
    • 機會
      • 胃癌治療方法和診斷技術不斷進步
    • 任務
      • 治療相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療分類的胃癌治療市場

  • 化療
  • 免疫療法
  • 放射治療及手術
  • 標靶治療

第7章胃癌治療市場：依疾病適應症分類

  • 胃癌/胃食道結合部癌
  • 胃腸道基質腫瘤

第8章按藥物類別分類的胃癌治療市場

  • HER2拮抗劑
  • PD-1/PD-L1抑制劑
  • VEGFR2拮抗劑

第9章胃癌治療市場：依途徑

  • 可注射的
  • 口服

第10章胃癌治療市場：依通路分類

  • 醫院藥房
  • 專業藥局和零售藥局

第11章 美洲胃癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區胃癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲胃癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Celltrion Healthcare Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline PLC
  • Imugene Limited
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck KGaA
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Samsung Bioepis Co., Ltd.
Product Code: MRR-F927BA461E32

The Stomach Cancer Treatment Market was valued at USD 5.09 billion in 2023, expected to reach USD 5.55 billion in 2024, and is projected to grow at a CAGR of 9.53%, to USD 9.63 billion by 2030.

The scope and definition of stomach cancer treatment encompass various therapeutic approaches aimed at managing or curing gastric cancer, including surgery, chemotherapy, targeted therapy, and immunotherapy. The necessity for treatment is underscored by the global burden of stomach cancer, as it ranks among the leading causes of cancer-related deaths worldwide, necessitating effective treatment strategies to improve patient outcomes and survival rates. Stomach cancer treatment is crucial in the application of personalized medicine, where therapies are tailored to the individual's genetic makeup and the cancer's molecular profile, fostering more precise and effective treatment regimens. The end-use scope primarily includes hospitals, cancer research centers, and specialized oncology clinics, where multidisciplinary teams deploy these treatments in the management of gastric cancer.

KEY MARKET STATISTICS
Base Year [2023] USD 5.09 billion
Estimated Year [2024] USD 5.55 billion
Forecast Year [2030] USD 9.63 billion
CAGR (%) 9.53%

Market insights reveal several key growth factors influencing the stomach cancer treatment landscape, notably advancements in targeted therapies and the increasing prevalence of the disease, which drives demand for innovative treatment options. Rising health awareness and improved diagnostic technologies also contribute to market growth, as they facilitate early detection and timely intervention. Moreover, the latest potential opportunities lie in developing next-generation immunotherapies and combination treatment regimens that promise to enhance efficacy and patient quality of life. Companies are recommended to invest in research collaborations and clinical trials to unlock these opportunities.

However, the market faces limitations and challenges including high treatment costs, variability in patient response to therapies, and limited access to advanced treatment options in developing regions. Regulatory hurdles and the complexity of conducting globally accepted clinical trials further complicate market expansion. For business growth, innovation can be driven by focusing on biomarkers for early detection and monitoring treatment response, enhancing drug delivery systems, and leveraging artificial intelligence to optimize treatment pathways. The nature of the market is highly competitive and research-intensive, necessitating continuous innovation and strategic partnerships to maintain a competitive edge and address unmet clinical needs effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Stomach Cancer Treatment Market

The Stomach Cancer Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population with a high risk for the development of stomach cancer
    • Increasing cases of diabetic and obese patients coupled with sedentary & unhealthy lifestyle
    • Growing emphasis on early screening and detection
  • Market Restraints
    • Dearth of gastroenterologists professionals and limited availability of scanning & treatment for timely diagnosis
  • Market Opportunities
    • Continuous technological advancements in treatments and diagnostic methods for stomach cancer
  • Market Challenges
    • Side effects related to treatments

Porter's Five Forces: A Strategic Tool for Navigating the Stomach Cancer Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Stomach Cancer Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Stomach Cancer Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Stomach Cancer Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Stomach Cancer Treatment Market

A detailed market share analysis in the Stomach Cancer Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Stomach Cancer Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Stomach Cancer Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Stomach Cancer Treatment Market

A strategic analysis of the Stomach Cancer Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Stomach Cancer Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., Eli Lilly and Company, F. Hoffmann La Roche Ltd., GlaxoSmithKline PLC, Imugene Limited, Jiangsu Hengrui Medicine Co., Ltd., Merck KGaA, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., and Samsung Bioepis Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Stomach Cancer Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy & Surgery, and Targeted Therapy.
  • Based on Disease Indication, market is studied across Gastric Cancer/Gastroesophageal Junction Cancer and Gastrointestinal Stromal Tumors.
  • Based on Drug Class, market is studied across HER2 Antagonists, PD-1/PD-L1 Inhibitors, and VEGFR2 Antagonists.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies and Specialty & Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population with a high risk for the development of stomach cancer
      • 5.1.1.2. Increasing cases of diabetic and obese patients coupled with sedentary & unhealthy lifestyle
      • 5.1.1.3. Growing emphasis on early screening and detection
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of gastroenterologists professionals and limited availability of scanning & treatment for timely diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous technological advancements in treatments and diagnostic methods for stomach cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects related to treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Stomach Cancer Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
  • 6.4. Radiation Therapy & Surgery
  • 6.5. Targeted Therapy

7. Stomach Cancer Treatment Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Gastric Cancer/Gastroesophageal Junction Cancer
  • 7.3. Gastrointestinal Stromal Tumors

8. Stomach Cancer Treatment Market, by Drug Class

  • 8.1. Introduction
  • 8.2. HER2 Antagonists
  • 8.3. PD-1/PD-L1 Inhibitors
  • 8.4. VEGFR2 Antagonists

9. Stomach Cancer Treatment Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral

10. Stomach Cancer Treatment Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Specialty & Retail Pharmacies

11. Americas Stomach Cancer Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Stomach Cancer Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Stomach Cancer Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Bayer AG
  • 3. Bristol Myers Squibb Company
  • 4. Celltrion Healthcare Co., Ltd.
  • 5. Eli Lilly and Company
  • 6. F. Hoffmann La Roche Ltd.
  • 7. GlaxoSmithKline PLC
  • 8. Imugene Limited
  • 9. Jiangsu Hengrui Medicine Co., Ltd.
  • 10. Merck KGaA
  • 11. Novartis AG
  • 12. Otsuka Pharmaceutical Co., Ltd.
  • 13. Pfizer, Inc.
  • 14. Samsung Bioepis Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. STOMACH CANCER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. STOMACH CANCER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. STOMACH CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. STOMACH CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STOMACH CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. STOMACH CANCER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY & SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGFR2 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY & RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. STOMACH CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. STOMACH CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023